Flagship leaders, Flagship-founded companies mark “Biotech’s Moment” throughout weeklong virtual gathering
CAMBRIDGE, Mass., January 11, 2020 -- Flagship Pioneering, a life science platforms company, today announced its participation in the JP Morgan Healthcare Conference 2021. A number of Flagship companies will present or announce new scientific advancements, research programs, partnerships and fundraising rounds throughout the week.
Flagship Pioneering will also host a conversation between Founder and CEO Noubar Afeyan and CNBC’s Senior Health and Science Reporter Meg Tirrell on Tuesday, January 12th at 3pm ET. The conversation will cover the latest news about Moderna’s mRNA-1273 vaccine and its deployment, Flagship’s increasing focus on Health Security and pre-emptive therapeutics, and why and how this is “biotech’s moment.” They will also take audience questions.
“Once defined by endless experimentation and expensive, lengthy and low probability-of-success drug development processes, biotechnology is now at the leading edge of technological progress, fusing rapidly advancing molecular science with a more deterministic path to products and impact,” said Noubar Afeyan, Ph.D., founder and CEO of Flagship Pioneering.
Flagship-founded companies presenting include:
- Moderna: Monday, January 11, 2021, 4:30pm ET
- Denali Therapeutics: Tuesday, January 12, 2021, 10:00am ET
- Repertoire Immune Medicines: Wednesday, January 13, 2021, 8:05am ET
- Rubius Therapeutics: Wednesday, January 13, 2021, 8:20am ET
- Omega Therapeutics: Wednesday, January 13, 2021, 9:50am ET
- Valo Health: Tuesday, January 12, 2021, 4:20pm ET
- Axcella Health: Thursday, January 14, 2021, 10:00am ET
- Seres: Thursday, January 14, 2021, 11:40am ET
- Kaleido Biosciences: Thursday, January 14, 2021, 2:00pm ET
- Syros: Thursday, January 14, 2021, 2:50pm ET
Flagship will be sharing content from company leaders as well as portfolio companies all week on LinkedIn and Twitter, using the hashtag #biotechmoment as well as #JPM2021.
About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $50 billion in aggregate value. To date, Flagship has deployed over $2.2 billion in capital toward the founding and growth of its pioneering companies alongside more than $18 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), Sigilon Therapeutics (NASDAQ: SGTX), and Syros Pharmaceuticals (NASDAQ: SYRS).